The Indian Health Ministry has proposed replacing a complex shelf-life rule with a simple 12-month requirement to reduce the wastage of imported medicines. Under a draft notification to amend Rule 31 of the Drugs Rules, 1945, most imported drugs must have at least one year of shelf life remaining upon entry into India, moving away from the current mandate that requires medicines to retain more than 60% of their total approved shelf life.
Why is the Health Ministry changing the drug import rules?
The current regulation creates a variable threshold for every drug. Because the requirement depends on the total shelf life of each specific medicine, different drugs must meet different remaining-life percentages before they can be imported. This complexity often leads to pharmaceutical products expiring during transit or storage due to rigid percentage-based calculations.
According to the ministry, the proposed amendment aims to improve efficiency across the pharmaceutical supply chain. By standardizing the requirement to a flat 12-month minimum, the government intends to reduce avoidable wastage, lower logistics costs, and improve inventory management for essential medicines.
Complex shelf-life rules can inadvertently increase the cost of life-saving drugs by forcing manufacturers to expedite shipping or face higher wastage rates during international transit.
How will this affect specialized and high-value medicines?
The ministry expects the change to significantly improve access to specialized treatments. The draft notification specifically highlights benefits for patients requiring cancer medicines and treatments for rare diseases. These high-value drugs often face stricter logistical hurdles due to their cost and specific storage needs.
Simplifying the import norms allows these critical medicines to enter the country with more predictable timelines. The ministry stated that this is a “pragmatic step” toward improving access for patients where public health importance justifies a more streamlined approach to shelf-life requirements.
Comparison of Import Requirements
| Feature | Current Rule (Rule 31) | Proposed Amendment |
|---|---|---|
| Requirement Basis | Percentage of total shelf life (>60%) | Fixed duration (Minimum 12 months) |
| Complexity | High (Varies by drug type) | Low (Standardized for most drugs) |
| Primary Goal | Strict percentage retention | Reducing wastage and improving access |
Will the new rules impact medicine safety or quality?
The Health Ministry clarified that the proposal does not alter any existing standards regarding the quality, safety, or efficacy of medicines. The amendment focuses strictly on the shelf-life requirement applicable at the time of import. All drugs must still comply with the established drug rules to ensure they are safe for public consumption.
By focusing on the timing of entry rather than the quality of the compound, the government seeks to balance regulatory oversight with the practicalities of global pharmaceutical logistics.
When monitoring new drug arrivals, always verify the specific manufacturer’s expiration date against the updated 12-month import standard to ensure compliance with local pharmacy inventory protocols.
Frequently Asked Questions
What is the main change in the proposed drug rule?
The proposal replaces the requirement to have 60% of a drug’s total shelf life remaining with a requirement that drugs have at least 12 months of shelf life left when imported.
Which types of medicines will benefit most?
Specialized cancer medicines and treatments for rare diseases are expected to see improved availability and reduced wastage.
Does this change how medicines are tested for safety?
No. The ministry stated that standards for quality, safety, and efficacy remain unchanged under the current drug rules.
What are your thoughts on these changes to pharmaceutical import laws? Share your views in the comments below or subscribe to our newsletter for more industry updates.